Research & Development at a glance
Ipsen’s commitment to research & development is our bold promise to patients to launch at least one new drug or meaningful new indication every year. We will secure our future by building a pipeline of innovative medicines, establishing our leadership position in key therapeutic areas, ensuring sustainable lifecycle management and, most importantly, creating a company of inspiring people throughout our R&D organization.
At a glance
In 2020, we invested €405.6 million in R&D, equivalent to 15.6% of sales.
We have 700 employees dedicated to R&D.
Our R&D activities are focused in Europe (France, Germany, Ireland & UK), USA and China.
Our 3 main R&D hubs are located in Paris-Saclay, France; Oxford in the UK and Cambridge in the USA and we have 5 other R&D sites located in China, France, Germany, Ireland and the UK.
We have seven clinical studies in Phase III.
Building a sustainable R&D pipeline
Clinical trials are a complex part of our industry so here we aim to present information on clinical trials in an informative and transparent manner. Here you will find information that will help deepen your understanding of what they are, why they are important and how to find one.
Our R&D power bases
We decided to locate our main R&D centres in world-class scientific hubs to take advantage of the networking opportunities and to progress our external innovation philosophy within established scientific ecosystems. Our three main sites are connected as an ‘innovation grid’, sharing real-time information, allowing us to adapt and focus capabilities to maximize our search and evaluation strategies on a global scale.
Our innovation teams are housed in a high-tech environment near Paris and are in close contact with major scientific and academic institutions. Established in 1969, the core mission of this site is to accelerate clinical development, translational and fundamental research to deepen our understanding of molecular, pharmacologic, pharmacodynamic and pharmacokinetic properties of new molecules in Oncology, Neuroscience and Rare Diseases.
The Milton Park site in Oxford is home to UK R&D functions and hosts about 100 employees including researchers devoted to R&D in Neuroscience, as well as other R&D professionals including regulatory affairs, pharmacovigilance, publications, clinical development and project management. This R&D centre has been designed to encourage innovation and foster collaboration. It is home to our technological platform for botulinum toxins and is a pioneering research and development organization with unique experience in recombinant botulinum toxin technology.
The Ipsen Bioscience R&D center in Cambridge in the USA is dedicated to a “Search & Evaluate” model to enhance the pipeline with clinical assets across all three Therapeutic Areas, but is primarily focused on Oncology and Rare Diseases. In addition, it hosts key functions essential to the delivery of clinical projects to market: the development team, tasked with coordinating and conducting worldwide clinical research, including in North America, and a dedicated regulatory group, which focuses on our regulatory activities with the FDA in the United States and Health Canada in Canada. The Cambridge facility positions Ipsen at the center of the biotech revolution and among the most exciting pioneers in the industry.
R&D power bases
Our R&D strategy
As a global biopharmaceutical company, with a focus on innovation and specialty care, we have the ambition to build a robust, valuable and sustainable portfolio of innovative medicines to meet our patient’s needs. Our R&D strategy is guided by our end goal to ensure that we bring innovative medicines to market as quickly as possible to address unmet patient needs in the areas of Oncology, Neuroscience and Rare Diseases.
The future success of our R&D model
This strategy is enabled by empowered, high-performing global project teams that include pharmaceutical development, non-clinical, clinical, digital and regulatory strategies to accelerate Ipsen’s development plans.
Creation of a development powerhouse
By integrating our core R&D functions of Pharmaceutical Development and Global Medical Affairs to build a professional organization which will lead the scientific and medical strategy for Ipsen.
Implementation of an external innovation sourcing model
This will enable us to access more opportunities and position ourselves as the partner of choice.
Our vision is based on scientific curiosity and risk-taking as we continue to innovate and push the frontiers of knowledge. To discover new targets, create innovative therapeutic treatments, and explore emerging fields, we have created unique partnerships at the very early stages of research tackling the major scientific challenges of the future. To develop new therapeutic solutions with significant clinical and patient benefits we need to explore new scientific ground and take calculated risks at each step along the way.
The patient always comes first and is central to our primary aims to provide patients with therapeutic solutions and define molecules with the desired efficacy and safety. Translational medicine is integrated into all R&D phases to lead the emergence of therapeutic concepts and guide the clinical research during the drug development process. The aim of this precision medicine approach is to accurately identify the patient group most likely to benefit from the proposed treatment and to optimize the use of new molecules.
Creativity feeds on multiple collaborations with both academic research and innovative companies. This tradition of collaborative efforts and partnerships is in our R&D DNA. The Group deploys a “win-win” approach with partners and internal teams to respond as quickly as possible to scientific and medical challenges.
Patients are at the forefront of everything we do
We want to provide safe and effective therapeutic solutions for our patients, many of whom suffer from very disabling conditions. Our patient-driven ethos depends upon the early engagement of patients in our research & development processes. We want to hear the voice of the patient in helping us to design and deliver clinical trials so we regularly hold patient advisory boards to gain appropriate input.
With over €1 billion to invest in building our pipeline, we have aspirations to acquire new medicines that are aligned with our focus and that bring synergies to our existing capabilities. We intend to deliver high double-digit growth by implementing our R&D transformation with a focus on innovative and differentiated therapeutics, and bolstering our external sourcing model, at the same time as expanding our portfolio.
Our R&D specialisms
In 2017, we achieved: